PersonGen BioTherapeutics (Suzhou) Co. Ltd. was registered and established in Suzhou Industrial Park on May 31, 2010. PersonGen, the abbreviation of Personalized Gene Therapy, implies devoting to the development of novel personalized medicine. The company was founded by Dr. Lin Yang who lead a group of international experts in the fields of oncology and immunology. The major goal of the company is to develop cutting-edge cellular immunotherapies for all cancer types. The company has been certificated by ISO9001 and recognized for numerous awards including, for example, Jiangsu High-Tech Private Enterprise, and Jiangsu Double Innovation Talent Program, Suzhou Gusu Innovating and Leading Talent Enterprise, Suzhou Industrial Park Technology Leading Talent Enterprise, Jiangsu Province Six Talents Peak Team, and National High-Tech Enterprise. The company has also established postdoctoral incubation workstations and Suzhou Cancer Immunotherapy Engineering Technology Research Center.
In the 10 years since PersonGen (Suzhou) was found, the company has established a professional R&D team in which more than 80% of the R&D scientists have doctoral or master degrees. The company has published more than 30 research articles in Cancer Cell, Cancer Research, Oncogene, Cancer Science and other journal magazines. The company has applied for more than 30 domestic and foreign invention patents, more than 10 of which has been approved. Also, the company has 18 registered trademarks; 16 of them have been authorized. PersonGen has registered 13 CAR-T and CAR-NK clinical trials on Clinicaltrials.gov, and officially launched clinical trials by collaborating with more than 10 medical centers in China.
PersonGen (Suzhou), as the company's upstream research center, is located in the BioBay of Suzhou Industrial Park. The research center was equipped with the most advanced and comprehensive instruments, which allows our scientists to carry out research and to develop the most innovative cell therapeutic products. The research capacity of PersonGen covers from the very early development of antigen binding domains, CAR structure optimization, CAR-T functional testing, to the in vivo efficacy verification. The research center has the most advanced CAR structure and function verification platform, in vivo efficacy verification platform, Safeγ UCAR-γδT cell drug development platform, induced pluripotent stem cell (iPSC)-derived allogeneic cell therapy Platform, and NanoBa bispecific antibody development platform.
The company specializes in the development of the first-in-class and best-in-class CAR-T cell therapies. Several of our cellular products, which cover most hematologic malignancies and some solid tumors, have entered POC clinical trial stage. The company is also actively developing bispecific antibody therapeutics and is committed to becoming a global leader in developing novel CAR-T cell therapeutics to benefit the majority of cancer patients.